2015 ASCO乳腺癌(BC)研究进展 oral-619

in , PW Whitworth, ME a , AM Brufsky , HM Gross, GS Soori , JO Hopkins, L Fehrenbacher , K Sturtz , TF Wozniak , TE Seay, EP Mamounas , N Wolmark Presented By Richard Margolese at 2015 ASCO Annual Meeting 背景 Presented By Richard Margolese at 2015 ASCO Annual Meeting ?乳房肿瘤切除术+放疗(RT) 是合适的方案?他莫昔芬辅助治疗降低: ?浸润性和非浸润性肿瘤复发?对侧原发乳腺癌既往 DCIS 研究担忧? DCIS 可能以浸润性乳腺癌的形式复发?可能为转移性疾病? SERMs 的不良竞争作用?子宫癌?血栓栓塞问题 Presented By Richard Margolese at 2015 ASCO Annual Meeting 实验依据雌激素通路不完全抑制?芳香化酶抑制剂(AI) 是否更好? 浸润性乳腺癌? AIs 比他莫昔芬更好?改善 DFS ?减少对侧乳腺癌的发生考虑 AI用于 DCIS Presented By Richard Margolese at 2015 ASCO Annual Meeting 10 NRG 肿瘤学/ NSABP B-35 方案绝经后女性采用乳房切除术治疗 DCIS ER 阳性或 PgR 阳性分层年龄(< 60 岁 vs. ≥ 60 岁)随机分组他莫昔芬(20mg/d) +安慰剂共用 5年+乳房放疗阿那曲唑(1mg/d) +安慰剂共用 5年+乳房放疗 Presented By Richard Margolese at 2015 ASCO Annual Meeting